EU Court Cuts Perindopril Fines For Krka And Servier
A ruling by the EU’s General Court has confirmed that agreements between Servier and several generics firms over perindopril constituted restrictions of competition. However, it has reduced by more than €100 million a fine on Servier and has eliminated entirely a fine on Krka.
You may also be interested in...
The UK’s National Health Service has been denied an attempt to pursue damages from Servier over high prices for perindopril stemming from the firm “practicing deceit on the European Patent Office and the English courts”.
Almost doubling its sales of valsartan in 2018 helped to push up Krka’s sales by 5% and its operating profit by 17%, the Slovenian company has reported.
A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.